{"success":true,"data":{"pressRelease":{"id":"38719","rtpr_id":"nWkr6ZGStz","ticker":"SCIB","exchange":"Nasdaq Stockholm","all_tickers":["SCIB"],"title":"Bulletin from the annual general meeting in SciBase Holding AB (publ)","author":"Cision","published_at":"2026-05-19T09:30:08.994Z","article_body":"SciBase\nToday, the annual general meeting 2026 has been held in SciBase Holding AB\n(publ) (\"SciBase\" or the \"Company\"). The general meeting resolved in\naccordance with the proposals presented in the notice to convene the meeting\n(which is available on the Company's website (www.scibase.com)).\n\nThe annual general meeting resolved:\n* to adopt the profit and loss statement and the balance sheet and the group\nprofit and loss statement and the group balance sheet for the financial year\n2025;\n \n* that no dividend shall be paid for the financial year 2025 and that the\nyear's result shall be carried forward;\n \n* to grant the board members and the CEO discharge from liability for the\nfinancial year 2025;\n* that the board of directors shall consist of four ordinary members without\ndeputy members and that a registered accounting firm shall be elected as\nauditor;\n \n* that the fees payable to the board of directors for the period until the end\nof the next annual general meeting shall be SEK 415,000 for the chairman of\nthe board and SEK 150,000 to each of the other ordinary board members (who are\nnot employed by a larger shareholder in the Company) and that fees payable to\nthe auditor are to be paid in accordance with approved invoices;\n \n* for the period until the end of the next annual general meeting, to re-elect\nJesper Høiland, Robert Molander, Diana Ferro and Anna Eriksrud as board\nmembers, to re-elect Jesper Høiland as chairman of the board of directors and\nto elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for\nthe Company, with Magnus Lagerberg as auditor in charge;\n \n* to adopt principles for the appointment of a nomination committee;\n \n* to amend the articles of association and to carry out a reverse share split,\nwhereby one hundred (100) existing shares will be consolidated into one (1)\nnew share (reverse share split 1:100). Following registration of the reverse\nshare split with the Swedish Companies Registration Office, the quota value\nper share increases from SEK 0.05 to SEK 5.00;\n* to implement stock option program consisting of a directed issue of warrants\nand approval of transfer of warrants for the fulfillment of the Company's\nobligations under the stock option program; and\n* to authorize the board of directors to increase the share capital through\nissuance of new shares, warrants and/or convertible debentures. Through\nissuances resolved upon with support from the authorisation - with deviation\nfrom the shareholders' preferential rights - the number of shares issued, or\nnumber of shares created in connection with exercise of warrants or conversion\nof convertibles, shall correspond to not more than a 20 per cent dilution of\nthe share capital and the number of shares and votes in the Company after such\nissue(s).\nInformation regarding the elected board members' education, experience,\nassignments and independence can be found on the Company's website\nhttps://investors.scibase.se/sv/bolagsstyrning/bolagsstammor.\n\nFor additional information, please contact:\nPia Renaudin, CEO\nPhone: +46 732 069 802\nE-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA):\n\nDNB Carnegie Investment Bank AB (publ)\n\nPhone: +46 8 588 68 570\n\nE-mail: certifiedadviser@carnegie.se\n\nAbout SciBase:\n\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops and commercializes\nNevisense, a unique point-of-care platform that combines AI (artificial\nintelligence) and advanced EIS technology to enhance diagnostic accuracy,\nensuring proactive skin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment\nBank AB (publ).  Learn more at www.scibase.com. For press releases and\nfinancial reports visit: http://investors.scibase.se/en/pressreleases\n\nhttps://news.cision.com/scibase/r/bulletin-from-the-annual-general-meeting-in-scibase-holding-ab--publ-%2Cc4350208\n\nSciBase - Bulletin AGM 2026 (ENG)\n(https://mb.cision.com/Main/12371/4350208/4101104.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr6ZGStz","title":"Bulletin from the annual general meeting in SciBase Holding AB (publ)","author":"Cision","ticker":"SCIB","created":"2026-05-19T09:30:08.994Z","tickers":["SCIB"],"exchange":"Nasdaq Stockholm","article_body":"SciBase\nToday, the annual general meeting 2026 has been held in SciBase Holding AB\n(publ) (\"SciBase\" or the \"Company\"). The general meeting resolved in\naccordance with the proposals presented in the notice to convene the meeting\n(which is available on the Company's website (www.scibase.com)).\n\nThe annual general meeting resolved:\n* to adopt the profit and loss statement and the balance sheet and the group\nprofit and loss statement and the group balance sheet for the financial year\n2025;\n \n* that no dividend shall be paid for the financial year 2025 and that the\nyear's result shall be carried forward;\n \n* to grant the board members and the CEO discharge from liability for the\nfinancial year 2025;\n* that the board of directors shall consist of four ordinary members without\ndeputy members and that a registered accounting firm shall be elected as\nauditor;\n \n* that the fees payable to the board of directors for the period until the end\nof the next annual general meeting shall be SEK 415,000 for the chairman of\nthe board and SEK 150,000 to each of the other ordinary board members (who are\nnot employed by a larger shareholder in the Company) and that fees payable to\nthe auditor are to be paid in accordance with approved invoices;\n \n* for the period until the end of the next annual general meeting, to re-elect\nJesper Høiland, Robert Molander, Diana Ferro and Anna Eriksrud as board\nmembers, to re-elect Jesper Høiland as chairman of the board of directors and\nto elect the auditing firm Öhrlings PricewaterhouseCoopers AB as auditor for\nthe Company, with Magnus Lagerberg as auditor in charge;\n \n* to adopt principles for the appointment of a nomination committee;\n \n* to amend the articles of association and to carry out a reverse share split,\nwhereby one hundred (100) existing shares will be consolidated into one (1)\nnew share (reverse share split 1:100). Following registration of the reverse\nshare split with the Swedish Companies Registration Office, the quota value\nper share increases from SEK 0.05 to SEK 5.00;\n* to implement stock option program consisting of a directed issue of warrants\nand approval of transfer of warrants for the fulfillment of the Company's\nobligations under the stock option program; and\n* to authorize the board of directors to increase the share capital through\nissuance of new shares, warrants and/or convertible debentures. Through\nissuances resolved upon with support from the authorisation - with deviation\nfrom the shareholders' preferential rights - the number of shares issued, or\nnumber of shares created in connection with exercise of warrants or conversion\nof convertibles, shall correspond to not more than a 20 per cent dilution of\nthe share capital and the number of shares and votes in the Company after such\nissue(s).\nInformation regarding the elected board members' education, experience,\nassignments and independence can be found on the Company's website\nhttps://investors.scibase.se/sv/bolagsstyrning/bolagsstammor.\n\nFor additional information, please contact:\nPia Renaudin, CEO\nPhone: +46 732 069 802\nE-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA):\n\nDNB Carnegie Investment Bank AB (publ)\n\nPhone: +46 8 588 68 570\n\nE-mail: certifiedadviser@carnegie.se\n\nAbout SciBase:\n\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops and commercializes\nNevisense, a unique point-of-care platform that combines AI (artificial\nintelligence) and advanced EIS technology to enhance diagnostic accuracy,\nensuring proactive skin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment\nBank AB (publ).  Learn more at www.scibase.com. For press releases and\nfinancial reports visit: http://investors.scibase.se/en/pressreleases\n\nhttps://news.cision.com/scibase/r/bulletin-from-the-annual-general-meeting-in-scibase-holding-ab--publ-%2Cc4350208\n\nSciBase - Bulletin AGM 2026 (ENG)\n(https://mb.cision.com/Main/12371/4350208/4101104.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-05-19T09:30:09.051518359Z","server_sent_at_ms":1779183009051},"received_at":"2026-05-19T09:30:09.138Z","source_url":"https://news.cision.com/scibase/r/bulletin-from-the-annual-general-meeting-in-scibase-holding-ab--publ-%2Cc4350208"},"analysis":{"id":"28160","press_release_id":"38719","analysis_json":{"industry":{"label":"Medical Devices","sector":"Health Care"},"redFlags":["1:100 reverse share split indicates severe listing compliance risk or illiquidity","No dividend paid for FY2025","Board authorized up to 20% dilution via new share issuance"],"eventType":"reverse_split","narrative":"SciBase Holding AB shareholders approved a 1:100 reverse share split at their annual general meeting, consolidating 100 existing shares into one new share.\n\nThe move increases the quota value per share from SEK 0.05 to SEK 5.00, a drastic measure typically taken to meet listing requirements or improve liquidity.\n\nThe meeting also resolved to pay no dividend for 2025, re-elected the board, and authorized the board to issue new shares representing up to 20% dilution of the share capital.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Extreme 1:100 reverse split signals critical listing risk for SciBase; watch for delisting threats or liquidity collapse."},"keyFigures":{"customDimensions":{"board_chair_fee":"SEK 415,000","new_quota_value":"SEK 5.00","old_quota_value":"SEK 0.05","board_member_fee":"SEK 150,000","reverse_split_ratio":"1:100","max_dilution_authorization":"20%"}},"quotedText":"to amend the articles of association and to carry out a reverse share split, whereby one hundred (100) existing shares will be consolidated into one (1) new share","namedEntities":{"people":[{"name":"Jesper Høiland","role":"Chairman of the Board"},{"name":"Robert Molander","role":"Board Member"},{"name":"Diana Ferro","role":"Board Member"},{"name":"Anna Eriksrud","role":"Board Member"},{"name":"Magnus Lagerberg","role":"Auditor in charge"},{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Öhrlings PricewaterhouseCoopers AB","relationship":"auditor"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified advisor"},{"name":"Karolinska Institute","relationship":"research partner"}],"dollarAmounts":[{"amount":"SEK 415,000","context":"fee for chairman of the board"},{"amount":"SEK 150,000","context":"fee for each ordinary board member"},{"amount":"SEK 0.05","context":"previous quota value per share"},{"amount":"SEK 5.00","context":"new quota value per share"}]},"materialImpact":{"score":4,"reasoning":"A 1:100 reverse share split is an extreme measure signaling severe listing compliance risk or liquidity issues. While it includes routine AGM resolutions (board re-election, no dividend), the magnitude of the split dominates the narrative."},"tickerRelevance":{"others":[],"primary":"SCIB"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":["board_change","dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"reverse_split_extreme","sectorWeight":"healthcare","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"reverse_split","event_type_secondary":["board_change","dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"SciBase Holding AB shareholders approved a 1:100 reverse share split at their annual general meeting, consolidating 100 existing shares into one new share.\n\nThe move increases the quota value per share from SEK 0.05 to SEK 5.00, a drastic measure typically taken to meet listing requirements or improve liquidity.\n\nThe meeting also resolved to pay no dividend for 2025, re-elected the board, and authorized the board to issue new shares representing up to 20% dilution of the share capital.","key_figures":{"customDimensions":{"board_chair_fee":"SEK 415,000","new_quota_value":"SEK 5.00","old_quota_value":"SEK 0.05","board_member_fee":"SEK 150,000","reverse_split_ratio":"1:100","max_dilution_authorization":"20%"}},"named_entities":{"people":[{"name":"Jesper Høiland","role":"Chairman of the Board"},{"name":"Robert Molander","role":"Board Member"},{"name":"Diana Ferro","role":"Board Member"},{"name":"Anna Eriksrud","role":"Board Member"},{"name":"Magnus Lagerberg","role":"Auditor in charge"},{"name":"Pia Renaudin","role":"CEO"}],"products":["Nevisense"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"Öhrlings PricewaterhouseCoopers AB","relationship":"auditor"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified advisor"},{"name":"Karolinska Institute","relationship":"research partner"}],"dollarAmounts":[{"amount":"SEK 415,000","context":"fee for chairman of the board"},{"amount":"SEK 150,000","context":"fee for each ordinary board member"},{"amount":"SEK 0.05","context":"previous quota value per share"},{"amount":"SEK 5.00","context":"new quota value per share"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T09:30:29.501Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"reverse_split_extreme","sectorWeight":"healthcare","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":20350,"modelName":"george-droid-qwen-72b"}}